search icon
      blog search icon

      Do You Know Why LPTX Stock Jumped 12% In Extended Trades? - Stocks Telegraph

      By ST Staff

      Published on

      July 8, 2021

      7:59 AM UTC

      Do You Know Why LPTX Stock Jumped 12% In Extended Trades? - Stocks Telegraph

      On the last check Wednesday, shares of the biotechnology company focused on developing targeted and immuno-oncology therapeutics, Leap Therapeutics Inc. (LPTX) was up 12.24% at $1.65 in after-hours trading. Leap stock lost -3.29% in the regular trading to conclude the session at $1.47. LPTX shares traded between $1.445 and $1.54.

      Over the last 100 days, LPTX stock was traded for 0.42 million shares, less than its volume of 0.56 million shares traded in past session. In the last five days, LPTX shares have dropped -12.50%, while they have dropped -16.95% in the last month. LPTX stock increased on news that the company’s CEO will present a corporate overview of the company at a virtual health conference.

      Where will LPTX be presenting?

      In addition to targeted therapies, Leap Therapeutics develops products for immuno-oncology. Clinically advanced candidate DKN-01, developed by LPTX, targets the Dickkopf-1 protein (DKK1). Clinical trials involving LPTX’s DKN-01 are being conducted in esophagogastric, hepatobiliary, gynecological, and prostate cancer patients. DKN-01 will be developed by LPTX in Asia, Australia, and New Zealand in partnership with BeiGene, Ltd.

      As part of the Ladenburg Thalmann 2021 Virtual Healthcare Conference, Leap Therapeutics will be represented by Douglas E. Onsi, the company’s President and Chief Executive Officer. LPTX executive will present on Wednesday, July 14, 2021, at 1:00 pm Eastern Time. Live webcast of the presentation will be available on the Investors page of the LPTX website. For a limited time, LPTX will also offer a replay of the event on its website.

      Leap Therapeutics has developed an image analysis assay called RNAscope, which is currently being used to enroll prospective patients in clinical trials.

      • LPTX is aware of no prior RNAscope study using a digital image analysis solution for patient enrollment.
      • On May 10, Scientific Reports published LPTX’s study findings.
      • LPTX’s article was titled: “Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.”
      • Biomarker tests must be precise and robust to be used in prospective patient identification.
      • Due to the difficulty associated with manually semi-quantifying RNAscope tissue staining, LPTX and Flagship developed a novel imaging algorithm designed to identify cancer cells and quantify the DKK1 signal.

      Is LPTX benefited by this collaboration?

      Leap Therapeutics (LPTX) developed a digital algorithm that replaces manual quantification, which can be time-consuming, inaccurate, and non-reproducible. Using the digital algorithm, pathologists save time, reduce the possibility of error in manual scoring, and enable LPTX to screen patients more reliably for possible treatment benefits.

      More From Stocks telegraph